Our lead product, ORION, uses the well known tumor marker Her2/Neu to deliver novel BCG and CMV-derived multi-epitope "Trojan horse" into tumors where they bind multiple MHC molecules and migrate as MHC-epitope complexes to the cell membrane. At that point, tumor cells presenting these multiple

MHC-epitope complexes are sensitive to the robust anti-BCG and anti-CMV T-cell immunity pre-exist in cancer patients (See illustration). The novelty of our technology stems from the special properties of signal peptides (SP) as multi-epitopes having a broader MHC binding in each patient and a dedicated

ER-localization (our 7 publications in mice and human studies).

IMYUN Pharmaceuticals's ORION already completed an in-vitro and in-vivo (mice) POC for tumor specificity, anti-tumor efficacy with a novel ability to change the tumor microenvironment.